Cargando…

Semi-experimental assessment of neutron equivalent dose and secondary cancer risk for off-field organs in glioma patients undergoing 18-MV radiotherapy

Neutron contamination as a source of out-of-field dose in radiotherapy is still of concern. High-energy treatment photons have the potential to overcome the binding energy of neutrons inside the nuclei. Fast neutrons emitting from the accelerator head can directly reach the patient’s bed. Considerin...

Descripción completa

Detalles Bibliográficos
Autores principales: Elmtalab, Soheil, Abedi, Iraj, Alirezaei, Zahra, Choopan Dastjerdi, Mohammad Hossein, Geraily, Ghazale, Karimi, Amir Hossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9337694/
https://www.ncbi.nlm.nih.gov/pubmed/35905102
http://dx.doi.org/10.1371/journal.pone.0271028
_version_ 1784759809252261888
author Elmtalab, Soheil
Abedi, Iraj
Alirezaei, Zahra
Choopan Dastjerdi, Mohammad Hossein
Geraily, Ghazale
Karimi, Amir Hossein
author_facet Elmtalab, Soheil
Abedi, Iraj
Alirezaei, Zahra
Choopan Dastjerdi, Mohammad Hossein
Geraily, Ghazale
Karimi, Amir Hossein
author_sort Elmtalab, Soheil
collection PubMed
description Neutron contamination as a source of out-of-field dose in radiotherapy is still of concern. High-energy treatment photons have the potential to overcome the binding energy of neutrons inside the nuclei. Fast neutrons emitting from the accelerator head can directly reach the patient’s bed. Considering that modern radiotherapy techniques can increase patient survival, concerns about unwanted doses and the lifetime risk of fatal cancer remain strong or even more prominent, especially in young adult patients. The current study addressed these concerns by quantifying the dose and risk of fatal cancer due to photo-neutrons for glioma patients undergoing 18-MV radiotherapy. In this study, an NRD model rem-meter detector was used to measure neutron ambient dose equivalent, H*(10), at the patient table. Then, the neutron equivalent dose received by each organ was estimated concerning the depth of each organ and by applying depth dose corrections to the measured H*(10). Finally, the effective dose and risk of secondary cancer were determined using NCRP 116 coefficients. Evidence revealed that among all organs, the breast (0.62 mSv/Gy) and gonads (0.58 mSv/Gy) are at risk of photoneutrons more than the other organs in such treatments. The neutron effective dose in the 18-MV conventional radiotherapy of the brain was 13.36 mSv. Among all organs, gonads (6.96 mSv), thyroid (1.86 mSv), and breasts (1.86 mSv) had more contribution to the effective dose, respectively. The total secondary cancer risk was estimated as 281.4 cases (per 1 million persons). The highest risk was related to the breast and gonads with 74.4 and, 34.8 cases per 1 million persons, respectively. Therefore, it is recommended that to prevent late complications (secondary cancer and genetic effects), these organs should be shielded from photoneutrons. This procedure not only improves the quality of the patient’s personal life but also the healthy childbearing in the community.
format Online
Article
Text
id pubmed-9337694
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-93376942022-07-30 Semi-experimental assessment of neutron equivalent dose and secondary cancer risk for off-field organs in glioma patients undergoing 18-MV radiotherapy Elmtalab, Soheil Abedi, Iraj Alirezaei, Zahra Choopan Dastjerdi, Mohammad Hossein Geraily, Ghazale Karimi, Amir Hossein PLoS One Research Article Neutron contamination as a source of out-of-field dose in radiotherapy is still of concern. High-energy treatment photons have the potential to overcome the binding energy of neutrons inside the nuclei. Fast neutrons emitting from the accelerator head can directly reach the patient’s bed. Considering that modern radiotherapy techniques can increase patient survival, concerns about unwanted doses and the lifetime risk of fatal cancer remain strong or even more prominent, especially in young adult patients. The current study addressed these concerns by quantifying the dose and risk of fatal cancer due to photo-neutrons for glioma patients undergoing 18-MV radiotherapy. In this study, an NRD model rem-meter detector was used to measure neutron ambient dose equivalent, H*(10), at the patient table. Then, the neutron equivalent dose received by each organ was estimated concerning the depth of each organ and by applying depth dose corrections to the measured H*(10). Finally, the effective dose and risk of secondary cancer were determined using NCRP 116 coefficients. Evidence revealed that among all organs, the breast (0.62 mSv/Gy) and gonads (0.58 mSv/Gy) are at risk of photoneutrons more than the other organs in such treatments. The neutron effective dose in the 18-MV conventional radiotherapy of the brain was 13.36 mSv. Among all organs, gonads (6.96 mSv), thyroid (1.86 mSv), and breasts (1.86 mSv) had more contribution to the effective dose, respectively. The total secondary cancer risk was estimated as 281.4 cases (per 1 million persons). The highest risk was related to the breast and gonads with 74.4 and, 34.8 cases per 1 million persons, respectively. Therefore, it is recommended that to prevent late complications (secondary cancer and genetic effects), these organs should be shielded from photoneutrons. This procedure not only improves the quality of the patient’s personal life but also the healthy childbearing in the community. Public Library of Science 2022-07-29 /pmc/articles/PMC9337694/ /pubmed/35905102 http://dx.doi.org/10.1371/journal.pone.0271028 Text en © 2022 Elmtalab et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Elmtalab, Soheil
Abedi, Iraj
Alirezaei, Zahra
Choopan Dastjerdi, Mohammad Hossein
Geraily, Ghazale
Karimi, Amir Hossein
Semi-experimental assessment of neutron equivalent dose and secondary cancer risk for off-field organs in glioma patients undergoing 18-MV radiotherapy
title Semi-experimental assessment of neutron equivalent dose and secondary cancer risk for off-field organs in glioma patients undergoing 18-MV radiotherapy
title_full Semi-experimental assessment of neutron equivalent dose and secondary cancer risk for off-field organs in glioma patients undergoing 18-MV radiotherapy
title_fullStr Semi-experimental assessment of neutron equivalent dose and secondary cancer risk for off-field organs in glioma patients undergoing 18-MV radiotherapy
title_full_unstemmed Semi-experimental assessment of neutron equivalent dose and secondary cancer risk for off-field organs in glioma patients undergoing 18-MV radiotherapy
title_short Semi-experimental assessment of neutron equivalent dose and secondary cancer risk for off-field organs in glioma patients undergoing 18-MV radiotherapy
title_sort semi-experimental assessment of neutron equivalent dose and secondary cancer risk for off-field organs in glioma patients undergoing 18-mv radiotherapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9337694/
https://www.ncbi.nlm.nih.gov/pubmed/35905102
http://dx.doi.org/10.1371/journal.pone.0271028
work_keys_str_mv AT elmtalabsoheil semiexperimentalassessmentofneutronequivalentdoseandsecondarycancerriskforofffieldorgansingliomapatientsundergoing18mvradiotherapy
AT abediiraj semiexperimentalassessmentofneutronequivalentdoseandsecondarycancerriskforofffieldorgansingliomapatientsundergoing18mvradiotherapy
AT alirezaeizahra semiexperimentalassessmentofneutronequivalentdoseandsecondarycancerriskforofffieldorgansingliomapatientsundergoing18mvradiotherapy
AT choopandastjerdimohammadhossein semiexperimentalassessmentofneutronequivalentdoseandsecondarycancerriskforofffieldorgansingliomapatientsundergoing18mvradiotherapy
AT gerailyghazale semiexperimentalassessmentofneutronequivalentdoseandsecondarycancerriskforofffieldorgansingliomapatientsundergoing18mvradiotherapy
AT karimiamirhossein semiexperimentalassessmentofneutronequivalentdoseandsecondarycancerriskforofffieldorgansingliomapatientsundergoing18mvradiotherapy